Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 1;8(11):14932-8.
eCollection 2015.

C-MET overexpression and amplification in gliomas

Yoonjin Kwak  1 , Seong-Ik Kim  1 , Chul-Kee Park  2 , Sun Ha Paek  2 , Soon-Tae Lee  3 , Sung-Hye Park  4
Affiliations

C-MET overexpression and amplification in gliomas

Yoonjin Kwak et al. Int J Clin Exp Pathol. .

Abstract

We investigated c-Met overexpression and MET gene amplification in gliomas to determine their incidence and prognostic significance. c-Met immunohistochemistry and MET gene fluorescence in situ hybridization were carried out on tissue microarrays from 250 patients with gliomas (137 grade IV GBMs and 113 grade II and III diffuse gliomas). Clinicopathological features of these cases were reviewed. c-Met overexpression and MET gene amplification were detected in 13.1% and 5.1% of the GBMs, respectively. All the MET-amplified cases showed c-Met overexpression, but MET amplification was not always concordant with c-Met overexpression. None of grade II and III gliomas demonstrated c-Met overexpression or MET gene amplification. Mean survival of the GBM patients with MET amplification was not significantly different from patients without MET amplification (P=0.155). However, GBM patients with c-Met overexpression survived longer than patients without c-Met overexpression (P=0.035). Although MET amplification was not related to poor GBM prognosis, it is partially associated with the aggressiveness of gliomas, as MET amplification was found only in grade IV, not in grade II and III gliomas. We suggest that MET inhibitor therapy may be beneficial in about 5% GBMs, which was the incidence of MET gene amplification found in the patients included in this study.

Keywords: Brain tumor; FISH; c-Met; glioblastoma; immunohistochemistry; target therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative images of glioblastomas with (A) diffuse c-Met overexpression, (B) lack of c-Met immunopositivity, (C) MET gene amplification, and (D) no MET gene amplification. (A, B: c-Met immunohistochemistry, ×400; C, D: Labeled locus-specific dual-color Vysis probe of MET gene (7q31), spectrum orange/CEP7 Spectrum green, ×1000).
Figure 2
Figure 2
(A) Kaplan-Meier survival analysis revealed that patient survival was not related with MET gene amplification, but that (B) patients with c-Met overexpression had better survival than those without c-Met overexpression.
See this image and copyright information in PMC

References

    1. Lee CH, Jung KW, Yoo H, Park S, Lee SH. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010;48:145–152. - PMC - PubMed
    1. Pierscianek D, Kim YH, Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Wrede K, Nakazato Y, Tanaka Y, Mariani L, Vital A, Sure U, Ohgaki H. MET gain in diffuse astrocytomas is associated with poorer outcome. Brain Pathol. 2013;23:13–18. - PMC - PubMed
    1. Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, Dong SM, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140–148. - PubMed
    1. Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O’Rourke TJ, Marincola FM, Vande Woude GF. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 2012;109:570–575. - PMC - PubMed
    1. Uchinokura S, Miyata S, Fukushima T, Itoh H, Nakano S, Wakisaka S, Kataoka H. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. Int J Cancer. 2006;118:583–592. - PubMed

Publication types

Substances